PATENT CLAIM ANALYSIS

Application Number: 15743622
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-07
Patent Classification: ["514", "029000"]

Abstract:
The present invention provides a therapeutic agent for myotonic dystrophy which inhibits aberrant splicing responsible for myotonic dystrophy, resulting in an increase in a normally spliced product and thus improvement in a symptom of myotonic dystrophy, and is highly safe for use in long-term administration. The therapeutic agent for myotonic dystrophy comprises, as an active ingredient, at least one compound selected from the group consisting of erythromycin, clarithromycin and azithromycin, a pharmaceutically acceptable salt or hydrate thereof, or a prodrug thereof.

Claim (Index 10):
The method according to  claim 9 , wherein the genes of which the aberrant splicing occurs is selected from the group consisting of ATP2A1, CLCN1, INSR, DMD, MBNL1 and BIN1.

Metadata:
- Claim Count in Document: 3.0
- Percentile: 86.0
- Lexical Diversity: 1.55172
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['14431115', '10591883', '14297137', '14352717', '12918696']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.766184095047496
- 35 USC 102 Novelty (BERT): 0.5213676135288302
- Combined Prediction Score: 0.7417024468956294
- Mean Citation Score: 238.43940200000003
- Max Citation Score: 268.1818
- Similarity Product: 161.65807397453784

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test